Pfizer (PFE) SVP trims stake with 2,000-share stock sale

Rhea-AI Filing Summary

Pfizer Inc. reported that SVP & Controller Jennifer B. Damico executed an open-market sale of 2,000 shares of Pfizer common stock on June 9, 2026 at $25.70 per share. Following this transaction, she directly holds 31,397 Pfizer common shares.

Insider Trade Summary

Net Seller: 2,000 shares ($51,400)

Net Sell 1 txn

Insider DAMICO JENNIFER B.

Role SVP & Controller

Sold 2,000 shs ($51K)

Type	Security	Shares	Price	Value
Sale	Common Stock	2,000	$25.70	$51K

Holdings After Transaction: Common Stock — 31,397 shares (Direct, null)

Footnotes (1)

Key Figures

Shares sold: 2,000 shares Sale price: $25.70 per share Shares held after transaction: 31,397 shares +1 more

4 metrics

Shares sold 2,000 shares Open-market sale on June 9, 2026

Sale price $25.70 per share Open-market transaction

Shares held after transaction 31,397 shares Direct ownership post-sale

Net shares sold 2,000 shares Net-sell direction in transaction summary

Key Terms

open-market sale, Common Stock, Form 4

3 terms

open-market sale financial

"transaction_action: "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Common Stock financial

"security_title: "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 regulatory

"This officer role is identified in the Form 4 filing"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

DAMICO JENNIFER B.

(Last) (First) (Middle)

66 HUDSON BOULEVARD EAST

ATTN: CORPORATE SECRETARY

(Street)

NEW YORK NEW YORK 10001-2192

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PFIZER INC [ PFE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP & Controller

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/09/2026		S		2,000	D	$25.7	31,397	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Shanice A. Reid, by power of atty, for Jennifer B. Damico	06/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Pfizer (PFE) report for Jennifer B. Damico?

Pfizer reported that SVP & Controller Jennifer B. Damico sold 2,000 shares of common stock in an open-market transaction at $25.70 per share. After this sale, she directly holds 31,397 Pfizer common shares according to the Form 4 disclosure.

What price did the Pfizer (PFE) insider sale occur at?

The reported insider sale occurred at $25.70 per share for Pfizer common stock. Jennifer B. Damico sold 2,000 shares in an open-market transaction at this price, as disclosed in the Form 4 filing with post-transaction holdings also reported.

How many Pfizer (PFE) shares does Jennifer B. Damico hold after the sale?

After the transaction, Jennifer B. Damico directly holds 31,397 Pfizer common shares. This figure comes from the Form 4, which shows her position immediately following the open-market sale of 2,000 shares at $25.70 per share.

What role does Jennifer B. Damico hold at Pfizer (PFE)?

Jennifer B. Damico is Pfizer’s Senior Vice President & Controller. This officer role is identified in the Form 4 filing, which reports her open-market sale of 2,000 Pfizer common shares and her resulting direct ownership of 31,397 shares.

Was the Pfizer (PFE) insider transaction a buy or a sell?

The transaction was a sale. The Form 4 lists transaction code “S” and describes it as an open-market sale of 2,000 Pfizer common shares at $25.70 per share by SVP & Controller Jennifer B. Damico.